James M. Stankiewicz, MD
Assistant Professor of Neurology
Harvard Medical School
Clinical Director, Partners Multiple Sclerosis Center
Jiwon Oh, MD, PhD, FRCPC
Assistant Professor, Division of Neurology
St. Michael's Hospital, University of Toronto
Assistant Professor, Department of Neurology
Johns Hopkins School of Medicine
Staff Neurologist, St. Michael's Hospital
Scientist, Keenan Research Centre of the
Li Ka Shing Knowledge Institute
0.5 AMA PRA Category 1 Credit ™
Progressive MS is characterized by a steadily increasing, objectively documented course of neurologic disability. The diagnosis of progressive forms of MS, primary progressive MS (PPMS) and secondary progressive MS (SPMS) can be challenging, and consequently many patients have untreated disease for years before they are appropriately diagnosed. Management can also be difficult due to the heterogeneous and unpredictable nature of MS, and a limited number of therapeutic options that have been shown to reduce disability progression. This activity will address diagnostic criteria for PPMS and SPMS, the latest guidelines for the management of progressive MS phenotypes, and the efficacy, safety and appropriate use of existing and late-phase investigational therapies for PPMS and SPMS.
There are many key points addressed in this virtual meeting. Clinicians may find the additional information and resources below useful.
Frequently Asked Questions
This educational activity is designed to meet the needs of neurology clinicians (including physicians, NPs, PAs) and others who encounter patients with MS.
Upon completion of this educational activity, the participant should be able to:
- Discuss the diagnostic criteria for SPMS and PPMS.
- Describe the evidence-based efficacy and safety of existing and late-stage investigational DMTs for the management of PPMS.
- Discuss the evidence-based efficacy and safety of existing and late-stage investigational DMTs for the management of SPMS.
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.
Dr. Stankiewicz discloses the following:
Consultant: EMD-Serono, Sanofi-Genzyme, Genentech
Advisory Board Membership: Novartis, Celgene, Biogen-Idec
Dr. Oh discloses the following:
Grants/research support: Roche, Biogen-Idec, Sanofi-Genzyme
Consultant: Roche, Biogen-Idec, Sanofi-Genzyme, Celgene, EMD-Serono
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support Statements
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Instructions for Credit
- Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 30, 2019, through August 30, 2020:
A. Register online at http://www.clinicaloptions.com.
B. Read the target audience, learning objectives, and faculty disclosures.
C. Study the educational activity online or printed out.
D. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 80% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
© 2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University, or Novartis Pharmaceuticals Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.